Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552813 | 1.00 | HRH3 (0.61) | HRH3KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL1397942 | 0.94 | HRH3 (0.68) | HRH3KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL5024198 | 0.92 | HRH3 (0.59) | HRH3KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL5023593 | 0.86 | HRH3 (0.66) | HRH3KMT2A | |
| SCHEMBL5023289 | 0.86 | HRH3 (0.66) | HRH3KMT2A | |
| SCHEMBL5023499 | 0.86 | HRH3 (0.66) | HRH3KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL5017044 | 0.85 | HRH3 (0.60) | HRH3 | |
| SCHEMBL5023225 | 0.84 | HRH3 (0.59) | HRH3 | |
| SCHEMBL5017033 | 0.83 | HRH3 (0.86) | HRH3RAB9ANPC1 | |
| SCHEMBL5024117 | 0.83 | HRH3 (0.80) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968967-B1 | 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-7538101-B2 | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1968967-A1 | 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1761519-B1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7361682-B2 | Indole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007062997-A1 | 1,1-DIOXO-THIOMORPHOLINYL INDOLYL METHANONE DERIVATIVES FOR USE AS H3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123526-A1 | 1,1-Dioxo-thiomorpholinyl indolyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | US | disclosed |
| EP-1761519-A1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123716-A1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HRH3, HRH4, ADRB1 | HRH3 1/4885KDM4E 1001/4885ALDH1A1 2007/4885 |
| US-20070123526-A1 | 1,1-Dioxo-thiomorpholinyl indolyl methanone derivatives | MTNR1A, HTR1A, HRH4 | HRH3 4/4885KDM4E 2092/4885ALDH1A1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.